NCT05166031View on ClinicalTrials.gov

Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

October 18, 2021

Conditions
Poliomyelitis
Interventions
BIOLOGICAL

bOPV and nOPV2

Approximately 265 subjects will receive 2 doses of bOPV, nOPV2 or bOPV + nOPV2 per arm separated by 28 days between doses.

Sponsors

Lead Sponsor

Fidec Corporation
All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Fidec Corporation

OTHER

NCT05166031 - Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine | Biotech Hunter | Biotech Hunter